Revance Therapeutics Inc
General ticker "RVNC" information:
- Sector: Health Care
- Industry: Pharmaceuticals
- Capitalization: $360.5M
Revance Therapeutics Inc does not follow the US Stock Market performance with the rate: -10.2%.
Estimated limits based on current volatility of -0.1%: low 3.08$, high 3.08$
Factors to consider:
- Current price 21.4% below estimated low
- Earnings for 9 months up through Q3 exceed our estimates
Stock Forecast*
* forecast is subjective and experimental, should not be used for any investment decisions
Long term estimates were made for the period from 2023-12-31 to 2025-12-30
- 2023-12-31 to 2024-12-30 estimated range: [3.92$, 11.63$]
- 2024-12-30 to 2025-12-30 estimated range: [3.33$, 9.20$]
Financial Metrics affecting the RVNC estimates:
- Negative: Non-GAAP EPS, $ of -2.90 <= 0.10
- Negative: Operating profit margin, % of -57.51 <= 1.03
- Negative: Operating cash flow per share per price, % of -25.15 <= 2.35
- Negative: Industry operating cash flow per share per price (median), % of -12.63 <= 3.85
- Negative: negative Net income
- Negative: Industry earnings per price (median), % of -15.01 <= 1.31
- Positive: Industry inventory ratio change (median), % of -2.41 <= -0.39
Short-term RVNC quotes
Long-term RVNC plot with estimates
Financial data
| YTD | 2021-12-31 | 2022-12-31 | 2023-12-31 |
|---|---|---|---|
| Operating Revenue | $77.80MM | $132.56MM | $234.04MM |
| Operating Expenses | $352.47MM | $474.52MM | $550.82MM |
| Operating Income | $-274.68MM | $-341.96MM | $-316.78MM |
| Non-Operating Income | $-6.63MM | $-13.76MM | $-6.91MM |
| Interest Expense | $6.27MM | $16.47MM | $19.36MM |
| R&D Expense | $116.25MM | $101.29MM | $79.41MM |
| Income(Loss) | $-281.31MM | $-355.72MM | $-323.69MM |
| Taxes | $0.00MM | $0.70MM | $0.30MM |
| Profit(Loss) | $-281.31MM | $-356.42MM | $-323.99MM |
| Stockholders Equity | $68.47MM | $12.60MM | $-151.60MM |
| Inventory | $10.15MM | $18.32MM | $45.58MM |
| Assets | $531.16MM | $581.90MM | $478.45MM |
| Operating Cash Flow | $-221.54MM | $-193.55MM | $-216.57MM |
| Capital expenditure | $18.07MM | $23.01MM | $6.89MM |
| Investing Cash Flow | $-29.66MM | $-138.80MM | $109.74MM |
| Financing Cash Flow | $29.87MM | $331.69MM | $136.57MM |
| Earnings Per Share* | $-4.25 | $-4.90 | $-3.83 |
* EPS are Split Adjusted, recent splits may be reflected with a delay.